Catalent, Inc. (NYSE:CTLT – Get Free Report) has earned an average rating of “Hold” from the thirteen analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, seven have assigned a hold recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $53.58.
CTLT has been the topic of a number of research analyst reports. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Catalent from $37.00 to $45.00 and gave the company a “hold” rating in a research note on Tuesday, August 15th. TheStreet cut shares of Catalent from a “c” rating to a “d+” rating in a research note on Monday, June 12th. Wells Fargo & Company initiated coverage on shares of Catalent in a research note on Thursday, July 20th. They issued an “equal weight” rating and a $43.00 target price on the stock. Robert W. Baird upped their price target on shares of Catalent from $35.00 to $47.00 in a research note on Tuesday, June 13th. Finally, William Blair restated a “market perform” rating on shares of Catalent in a research note on Wednesday, August 30th.
Insider Transactions at Catalent
Hedge Funds Weigh In On Catalent
A number of hedge funds and other institutional investors have recently bought and sold shares of CTLT. KB Financial Partners LLC purchased a new position in Catalent in the 1st quarter worth approximately $30,000. Compagnie Lombard Odier SCmA purchased a new position in Catalent in the 4th quarter worth approximately $34,000. FNY Investment Advisers LLC purchased a new position in Catalent in the 1st quarter worth approximately $34,000. Optiver Holding B.V. purchased a new position in Catalent in the 1st quarter worth approximately $35,000. Finally, Harel Insurance Investments & Financial Services Ltd. purchased a new stake in shares of Catalent in the 1st quarter valued at $48,000.
Catalent Stock Down 1.0 %
Catalent stock opened at $49.17 on Friday. The company has a debt-to-equity ratio of 0.93, a quick ratio of 1.27 and a current ratio of 1.78. The stock has a market cap of $8.86 billion, a PE ratio of -37.82, a price-to-earnings-growth ratio of 3.85 and a beta of 1.23. Catalent has a fifty-two week low of $31.45 and a fifty-two week high of $90.81. The firm’s 50-day simple moving average is $47.05 and its 200 day simple moving average is $49.12.
Catalent (NYSE:CTLT – Get Free Report) last released its earnings results on Tuesday, August 29th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.11 by ($0.02). The company had revenue of $1.09 billion during the quarter, compared to analysts’ expectations of $1.05 billion. Catalent had a negative net margin of 5.43% and a positive return on equity of 3.24%. The firm’s revenue was down 15.6% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.12 earnings per share. Research analysts predict that Catalent will post 0.7 EPS for the current fiscal year.
Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations.
- Five stocks we like better than Catalent
- 3 Healthcare Dividend Stocks to Buy
- China’s Jump In Car Sales Is Drawing Big Money To These Stocks
- How to Read Stock Charts for Beginners
- 3 Reasons Price Weakness Is a Buying Opportunity For Lennar
- What Investors Need to Know to Beat the Market
- Name A Better Trio Than These Underrated High Potential Stocks
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.